The CHARM-PRESERVED study demonstrated a moderate and borderline significant trend toward an 11% reduction in combined cardiovascular mortality or HF hospitalization with candesartan compared with the placebo [ 82 ].
← all excerpts
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.
1
—
—